



BeiGene

Financial Tear Sheet

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed five drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of July 2018, the Company had a global team of over 1,300 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.

Stock Information

BGNE (American Depositary Shares)

Exchange	NASDAQ GS (US Dollar)
----------	-----------------------

Price	\$157.32
-------	-----------------

Primary IR Contact

Investor Relations

E-mail:

ir@beigene.com

Change (%) **▲ 0.19 (0.12%)**

Volume 135,021

52 Week High \$220.10

52 Week Low \$65.59

Market Cap \$120,690,112,107

Rolling EPS -4.53

PE Ratio 0

Shares Outstanding 767,163,184

Data as of 08/17/18 4:00 p.m. ET

Press Releases

August 9, 2018

[BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China](#)

August 9, 2018

[BeiGene Reports Second Quarter 2018 Financial Results](#)

August 8, 2018

[BeiGene Announces Closing of Its HK\\$7.08 billion \(US\\$903 million\) Hong Kong Initial Public Offering and Global Offering](#)

SEC Filings

Filing Date	Form
08/15/18	4
08/13/18	8-K
08/09/18	10-Q
08/09/18	8-K

Upcoming Events

There are currently no events scheduled.

Corporate Governance

Governance Documents

 [Code of Business Conduct and Ethics](#)


 [Corporate Governance Guidelines](#)

 [Securityholder Communication Policy](#)

Committee Charters

 [Audit Committee](#)

 [Compensation Committee](#)

 [Nominating and Corporate Governance Committee](#)

Data provided by Nasdaq. Minimum 15 minutes delayed.

